Higher phospho-MARCKS levels are correlated with shorter overall survival of lung cancer patients, suggesting a key role for MARCKS in lung cancer and a therapeutic strategy for inhibiting PKC activity77. This evidence concerns the gene PRRT2 and lung cancer.